British-Swedish drugmaker AstraZeneca on Thursday said that its Covid-19 vaccine's efficacy at preventing symptomatic coronavirus was 76 per cent in a US phase-3 trial, slightly lower than 79 per cent efficacy that it projected earlier this week.
The revised efficacy estimate came after an independent board said that the 79 per cent efficacy results of the vaccine might have been based on outdated information.
This new efficacy analysis included the accrual of 190 symptomatic cases of Covid-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis, AstraZeneca said.
Participants were randomised on a 2:1 ratio between the vaccine and placebo group.
The results showed that vaccine efficacy at preventing symptomatic Covid-19 was 76 per cent occurring 15 days or more after receiving two doses given four weeks apart.
In addition, results were comparable across age groups, with vaccine efficacy of 85 per cent in adults 65 years and older.
A key secondary endpoint, preventing severe or critical disease and hospitalisation, demonstrated 100 per cent efficacy, the company said.
There were eight cases of severe Covid-19 observed in the primary analysis with all of those cases in the placebo group.
The vaccine was well tolerated, and no safety concerns related to the vaccine were identified, according to the data.
"The primary analysis is consistent with our previously released interim analysis, and confirms that our Covid-19 vaccine is highly effective in adults, including those aged 65 years and over," Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said in a statement.
"We look forward to filing our regulatory submission for Emergency Use Authorisation in the US and preparing for the rollout of millions of doses across America."
AstraZeneca said it will also submit the primary analysis for peer-reviewed publication in the coming weeks.
--IANS
gb/ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU